Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05263570
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
Sponsor: Shengjing Hospital
View on ClinicalTrials.gov
Summary
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
Official title: The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2022-08-01
Completion Date
2026-12-31
Last Updated
2022-09-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
Standard Therapy
Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
Locations (1)
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China